AU2002362098A8 - Methods of therapy for non-hodgkin's lymphoma - Google Patents

Methods of therapy for non-hodgkin's lymphoma

Info

Publication number
AU2002362098A8
AU2002362098A8 AU2002362098A AU2002362098A AU2002362098A8 AU 2002362098 A8 AU2002362098 A8 AU 2002362098A8 AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A8 AU2002362098 A8 AU 2002362098A8
Authority
AU
Australia
Prior art keywords
hodgkin
lymphoma
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002362098A
Other versions
AU2002362098A1 (en
Inventor
Sandra Milan
Maurice J Wolin
Deborah Hurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002362098A8 publication Critical patent/AU2002362098A8/en
Publication of AU2002362098A1 publication Critical patent/AU2002362098A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002362098A 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma Abandoned AU2002362098A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/017,968 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
US10/293,664 2002-11-12
PCT/US2002/039253 WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
AU2002362098A8 true AU2002362098A8 (en) 2003-06-23
AU2002362098A1 AU2002362098A1 (en) 2003-06-23

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002362098A Abandoned AU2002362098A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Country Status (5)

Country Link
EP (1) EP1463524A4 (en)
JP (1) JP2005538034A (en)
AU (1) AU2002362098A1 (en)
CA (1) CA2469045A1 (en)
WO (1) WO2003049694A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0316779B8 (en) 2002-12-16 2023-02-28 Genentech Inc HUMAN ANTI-CD20 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ITS USES, COMPOSITION, MANUFACTURED ARTICLE AND LIQUID FORMULATION
EP1629001A2 (en) 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2004308452A1 (en) * 2003-12-22 2005-07-14 Novartis Vaccines And Diagnostics, Inc. Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
CA2566745A1 (en) 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
BRPI0607351A2 (en) * 2005-02-15 2009-09-01 Novartis Vaccines & Diagnostic methods for treating lymphomas employing a combination of chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
MX354993B (en) 2007-07-09 2018-03-28 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides.
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2382058T3 (en) * 2008-01-17 2012-06-04 Philogen S.P.A. Combination of a fusion protein of an antibody directed against the fibronectin-IL-2 EDB, and a B-lymphocyte-binding molecule, progenitors of B-lymphocytes and / or their cancerous counterparts
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20200111282A (en) 2009-08-11 2020-09-28 제넨테크, 인크. Production of proteins in glutamine-free cell culture media
BR112012020102A2 (en) 2010-02-10 2016-11-29 Immunogen Inc cd20 antibodies and uses thereof.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
PE20231655A1 (en) 2015-10-02 2023-10-17 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
CN115369086B (en) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 Culture scheme for NK cell expansion culture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1267927A1 (en) * 2000-03-24 2003-01-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Also Published As

Publication number Publication date
EP1463524A2 (en) 2004-10-06
AU2002362098A1 (en) 2003-06-23
WO2003049694A2 (en) 2003-06-19
CA2469045A1 (en) 2003-06-19
WO2003049694A3 (en) 2003-11-06
JP2005538034A (en) 2005-12-15
EP1463524A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
AU2002362098A8 (en) Methods of therapy for non-hodgkin's lymphoma
GB2393202B (en) Methods of well treatment
AU2001247737A1 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
GB0111872D0 (en) Therapeutic agents and methods
IL161327A0 (en) Methods for treating ocular neovascular diseases
GB9824436D0 (en) Methods of treatment
AU2003225160A8 (en) "biosensor for dialysis therapy"
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
EP1077704A4 (en) Combination therapy for treatment of depression
EP1404871A4 (en) Method for treatment of cancer associated with elevated her 2 levels
EP1379242A4 (en) Method for treatment of cancer and compositions for use therein
EP1463495A4 (en) Agents and methods for treatment of cancer
GB0118383D0 (en) Therapeutic methods
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0124124D0 (en) Methods of treatment
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
GB0112216D0 (en) Method of treatment
EP1027007A4 (en) Dental treatment methods
GB0118892D0 (en) Method of treatment
GB0130763D0 (en) Treatment methods
IL161630A0 (en) Methods of treating endometreosis
EP1303281A4 (en) Methods of treatment
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002367463A8 (en) Novel p53bp2 compounds for therapy and diagnosis and methods for using same
GB0108772D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase